Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

Charles C Bell; Katie A Fenne; Yih-Chih Chan; Florian Rambow; Miriam M Yeung; Dane Vassiliadis; Luis Lara; Paul Yeh; Luciano G Martelotto; Aljosja Rogiers; Brandon E Kremer; Olena Barbash; Helai P Mohammad; Timothy M Johanson; Marian L Burr; Arindam Dhar; Natalie Karpinich; Luyi Tian; Dean S Tyler; Laura MacPherson; Junwei Shi; Nathan Pinnawala; Chun Yew Fong; Anthony T Papenfuss; Sean M Grimmond; Sarah-Jane Dawson; Rhys S Allan; Ryan G Kruger; Christopher R Vakoc; David L Goode; Shalin H Naik; Omer Gilan; Enid YN Lam; Jean-Christophe Marine; Rab K Prinjha; Mark A Dawson

Journal article

Targeting enhancer switching overcomes non-genetic drug resistance in acute myeloid leukaemia

Charles C Bell, Katie A Fenne, Yih-Chih Chan, Florian Rambow, Miriam M Yeung, Dane Vassiliadis, Luis Lara, Paul Yeh, Luciano G Martelotto, Aljosja Rogiers, Brandon E Kremer, Olena Barbash, Helai P Mohammad, Timothy M Johanson, Marian L Burr, Arindam Dhar, Natalie Karpinich, Luyi Tian, Dean S Tyler, Laura MacPherson Show all

Nature Communications | NATURE PUBLISHING GROUP | Published : 2019

DOI: 10.1038/s41467-019-10652-9

Download PDF

University of Melbourne Researchers

Mark Dawson Author The Sir Peter MacCallum Department of Oncology

Chih Chan Author The Sir Peter MacCallum Department of Oncology

Marian Burr Author The Sir Peter MacCallum Department of Oncology

Rhys Allan Author Medical Biology (W.E.H.I.)

Sarah-Jane Dawson Author The Sir Peter MacCallum Department of Oncology

Related Projects (3)

CLONAL EVOLUTION IN MYELODYSPLASIA AND ACUTE MYELOID LEUKAEMIA FOLLOWING AZACITIDINE

The myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) represent a spectrum of clinically heterogeneous malignancies that rema..

EPIGENETIC THERAPIES AS MOLECULAR PROBES TO INVESTIGATE THE MOLECULAR PATHOGENESIS OF LEUKAEMIA

A major limitation to the success of targeted therapies in cancer is the fact that we have few if any tools to study in detail their mechani..

MODELLING BET INHIBITOR RESISTANCE IN ACUTE MYELOID LEUKAEMIA

Mutations in epigenetic regulators in AML not only imply a causative role for these proteins in AML but also provide potential targets for t..

Grants

Awarded by Howard Hughes Medical Institute international research scholarship

Awarded by NHMRC

Awarded by Maddie Riewoldt's Vision

Awarded by FWO

Awarded by NATIONAL CANCER INSTITUTE

Funding Acknowledgements

We thank Gisela Arnau, Tim Semple, Jake Carmody and Tim Holloway for advice and assistance with genomic sequencing, Susan Jackson, Kimberly Smitheman and Jacob Rubin for experimental assistance and the members of the Dawson lab for experimental assistance, helpful comments and input into the manuscript. We thank O. Van Goethem for excellent technical assistance; PDX experiments were developed by TRACE with assistance of E. Leucci, L. Rizzotto, D. Thomas, E. Gomme and K. Crevits. The Tru-Sight26 analysis was performed by S. Vander Borght. We thank the following funders for Fellowship, Scholarship and grant support - Leukaemia Foundation Australia senior fellowship and Howard Hughes Medical Institute international research scholarship 55008729 (M.A.D.), CSL Centenary fellowship (S.-J.D.), NHMRC grant 1085015, 1106444 (M.A.D) and 1128984 (M.A.D, S.-J.D.), Snowdome Foundation (P.Y., M.A.D.), Maddie Riewoldt's Vision 064728 (Y.-C.C.), Victorian Cancer Agency (E.Y.N.L., L.M.), CRUK (M.L.B.) and FWO #G.0929.16 N (J.-C.M).